Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 14/20 | 0.70 |
| ▸ | BRD4 | O60885 | 6/20 | 0.68 |
| ▸ | KCNK3 | O14649 | 5/20 | 0.58 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.54 |
| ▸ | EP300 | Q09472 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10817478 | 0.86 | CREBBP (0.69) | CREBBPBRD4KCNK3 | |
| SCHEMBL19662970 | 0.83 | CREBBP (1.00) | CREBBPBRD4EP300 | |
| SCHEMBL17794686 | 0.81 | CREBBP (1.00) | CREBBPBRD4 | |
| SCHEMBL14791459 | 0.79 | KCNK3 (0.56) | CREBBPBRD4KCNK3 | |
| SCHEMBL14785030 | 0.79 | KCNK3 (0.77) | CREBBPBRD4KCNK3 | |
| SCHEMBL14784571 | 0.78 | KCNK3 (0.66) | CREBBPKCNK3 | |
| SCHEMBL7093107 | 0.77 | MAPK1 (0.65) | CREBBPBRD4KCNK3BAZ2BEP300 | |
| SCHEMBL14784144 | 0.77 | KCNK3 (0.73) | KCNK3 | |
| SCHEMBL14784984 | 0.75 | KCNK3 (1.00) | KCNK3 | |
| SCHEMBL14784804 | 0.75 | KCNK3 (1.00) | KCNK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030199544-A1 | Farnesyltransferase inhibitors | ABBOTT LABORATORIES | 2003-10-23 | — | — | US | disclosed |
| US-20030199542-A1 | Farnesyltransferase inhibitors | WEINSTOCK, STEVEN F. | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199542-A1 | Farnesyltransferase inhibitors | FNTA, FNTB, LCAT | CREBBP 900/4885BRD4 2471/4885KCNK3 4627/4885 |
| US-20030199544-A1 | Farnesyltransferase inhibitors | FNTA, FNTB, LCAT | CREBBP 900/4885BRD4 2471/4885KCNK3 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.